Medical Fluid Bags Market Analysis

Medical Fluid Bags Market Analysis

Regarding the product, the drain bags segment amassed around 29% medical fluid bags market share in 2022 and is estimated to exhibit notable growth over 2023-2032. The growing prevalence of lifestyle diseases such as diabetes and hypertension has led to a surge in end-stage renal disorders. As per the WHO, an estimated around 1.13 billion people across the globe are suffering due to hypertension. Diabetes is the leading cause of chronic kidney failure, followed by hypertension, which may affect around 422 million people worldwide. 

According to the University of California San Francisco research data, an estimated 2 million individuals globally suffer from renal failure. The number is expected to increase at a rate of 5-7% every year. The increasing incidences of acute or chronic renal failure (ARF or CRF) and the subsequent demand for medical fluid bags for urine collection will accelerate business trends.
 

With respect to end-use, the medical fluid bags market share from the hospital segment is expected to be worth over USD 2 billion by 2032. Medical fluid bags, also known as intravenous (IV) bags or infusion bags, are commonly used in healthcare settings to deliver fluids, medications, and nutrients directly into a patient's bloodstream. Increasing hospitalizations due to this surging prevalence rate of diarrheal diseases will propel the demand for medical fluid bags in hospital settings.

As per the WHO report, around 1.7 billion children below 5 years suffer from diarrheal disease annually. These facilities also ensure the availability of advanced diagnostic and medical procedures, such as dialysis, to patients suffering from chronic ailments. Furthermore, high-quality services and better-quality post-operative care across these establishments will augment segment gains. 
 

Looking for region specific data?

 Download Free Sample

Regionally, North America medical fluid bags market was valued at over USD 976 million in 2022, attributed to the rise in the geriatric population. According to the U.S. Census Bureau, in 2019, around 54.1 million people were 65 years and above in the U.S. The increasing aging population has contributed significantly to the growing disease burden over the past few years. Additionally, the presence of prominent players such as Thermo Fisher Scientific Inc., B. Braun Melsungen AG, and Amcor Ltd., among others, engaged in novel product development & commercialization will facilitate industrial expansion in North America.